Replies to post #798333 on NorthWest Biotherapeutics Inc (NWBO)

[sukus]

Omg, LP is thinking like Elon Musk. Elon too is several steps further.

[Chiugray]

Andrew, Worth noting again.

The phased Sawston buildout, the multiple SOW milestones, the acquisition of Advent, the Flaskworks development program, the simplified C lab design for automated scale, the redevelopment of the Grade B suites, and the internal language about preparing the facility for commercialization, all of it points to the same thing. They have already done the majority of the foundational work needed for rapid expansion once Eden is validated.

That is unusual in this space. Most companies wait for approval and then begin thinking about capacity. NWBO inverted that timeline. They built the infrastructure first. They validated processes first. They aligned the licensing first. They prepared the quality system first. They ensured that the cleanroom backbone exists now, not someday.

[Doc logic]

Slave1,

They also waited actively by improving on supply chain and various methods of activation for Direct until the new guidance put them into position to be able to take advantage immediately as Direct proves itself out radically and quickly in the first trial from restart. They will have ALL of the product release issues that L had before it could be approved taken care of before the start of any trial too. I expect lightning speed (for regulators that is) availability made to patients when Direct trials seem like they just got started. The new guidance by some regulators allows for this and I expect it to happen within the first year of trial start. That’s how well the science at this point says the patients will respond. Best wishes.

[sukus]

I think shorties here need to read the Slave1’s post here. So they don’t misjudge LP. LP is thinking much much further ahead. Misjudging LP will be very costly fir them I think. Friendly reminder shorties. Read the paragraphs slowly shorties.